Southern Research Institute Patent applications |
Patent application number | Title | Published |
20150232435 | UREA AND AMIDE DERIVATIVES OF AMINOALKYLPIPERAZINES AND USE THEREOF - Provided are compounds represented by the formula: with Y, Ri, and R2 being defined in the present disclosure; pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition capable of treatment with a partial agonist or antagonist of the dopamine D2/D3 receptors and are especially useful for patients suffering from schizophrenia, depressions, neurodegenerative diseases such as Parkinson's, dyskinesias, substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol, glaucoma, cognitive disorders, restless leg syndrome, attention deficit hyperactivity disorders, hyperprolactinemia, autism, motor disturbances such as akathisia, rigor, dystonias as well as various disorders of the urinary tract and other neurologic disorders. Also provided are processes for the preparation of compounds of the present disclosure. | 08-20-2015 |
20140336115 | Compounds, Compositions and Methods for the Treatment of Diseases Through Inhibiting TGF- Activity - The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (TGF-β). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g. multiple myeloma, hematologic malignancies), diseases associated with excessive TGF-β activity including fibrosis, dermal scarring, immune dysfunction, and bone loss by inhibiting the conversion of latent TGF-β to active TGF-β. A method of preventing the activation of TGF-β in pathology is also provided, comprising administering an amount of the compounds sufficient to inhibit conversion of latent TGF-β to active TGF-β by thrombospondinl (TSP1), resulting in reduced TGF-β activity and reduced adverse effects such as fibrosis, bone loss, and immune dysfunction. | 11-13-2014 |
20140256753 | QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS - Provided is a process for treating or preventing a viral infection in a subject, wherein the viral infection is from a flavivirus selected from the group consisting of Hepatitis C Virus (genotypes 1-7) and Japanese Encephalitis Virus. The process includes administering to the subject a therapeutically effective amount of at least one compound represented by the formula: (Formula (I)) | 09-11-2014 |
20140242027 | SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS - The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R | 08-28-2014 |
20140235582 | HIV REPLICATION INHIBITORS - Compounds of Formula (I) wherein B is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; Y is a linker moiety selected from the group consisting of a direct bond. R, R1, R2, and R3 are each individually selected from the group consisting substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or heterocycle. | 08-21-2014 |
20140199285 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS - A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a | 07-17-2014 |
20140127261 | Flavivirus Envelope Protein Mutations Affecting Virion Disassembly - Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope dimer protein to dissociate. | 05-08-2014 |
20140094492 | DERIVATIVES OF SULINDAC, USE THEREOF AND PREPARATION THEREOF - Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided. | 04-03-2014 |
20130330315 | ENHANCED THERAPEUTIC USAGE OF A PURINE NUCLEOSIDE PHOSPHORYLASE OR NUCLEOSIDE HYDROLASE - The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells. | 12-12-2013 |
20130296298 | TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF - The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. | 11-07-2013 |
20130236879 | THREE-DIMENSIONAL, PREVASCULARIZED, ENGINEERED TISSUE CONSTRUCTS, METHODS OF MAKING AND METHODS OF USING THE TISSUE CONSTRUCTS - Embodiments of the present disclosure provide for three-dimensional (3D), prevascularized, engineered tissue constructs, 3D prevascularized engineered tissue models of cancer, and bioreactors and bioreactor arrays including the tissue constructs. The present disclosure also provides methods of making the tissue constructs, methods of using the tissue constructs, methods of drug discovery using the tissue constructs and/or cancer models, and the like. | 09-12-2013 |
20130123240 | METHOD OF USING BIOTHIONOL AND BIOTHIONOL-LIKE COMPOUNDS AS ANTI-ANGIOGENIC AGENTS - The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine. | 05-16-2013 |
20130096175 | Compounds and Methods for Altering Lifespan of Eukaryotic Organisms - Provided are compounds which generally have a triketone structure. Examples of the compounds include derivatives of 1,3-cyclohexanedione, such as: 1,3-cyclohexanedione, 2-propanoyl-5-cyclohexyl-; 1,3-cyclohexanedione, 2-propanoyl-5-[4-fluorophenyl]-; 1,3-cyclohexanedione, 2-acetyl-5-[thien-2-yl]-; 1,3-cyclohexanedione, 2-acetyl-5-butyl-; and 1,3-cyclohexanedione, 2-propanoyl-5-[bicyclo[2.2.1]hept-2-en-5-yl]-. The compounds can be used to alter the lifespan of eukaryotic organisms and treat inflammation. | 04-18-2013 |
20130059811 | METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1: | 03-07-2013 |
20120309781 | TETRAHYDRO-beta-CARBOLINE DERIVATIVES, SYNTHESIS AND USE THEREOF - Certain 2-halophenyl, 2,4-dihalophenyl (e.g. 2,4-dichlorophenyl), 3,4-dichlorophenyl (e.g. 3,4-dichlorophenyl), 2,6-dichlorophenyl (2,6-dichlorophenyl) and 2,5-diakoxyphenyl (e.g. 2,5-dimethoxyphenyl) derivatives of tetrahydro-β-carbolines are provided, along with their pharmaceutically acceptable salts; prodrugs and solvates, and compositions containing the compounds. The compounds are useful for the prevention and treatment of cancer, and other indications where PDE5 inhibitors have shown benefits including erectile dysfunction, pulmonary hypertension, enhancing cognitive function, cystic fibrosis, or enhancing the activity of conventional chemotherapeutic drugs. Methods for fabricating the compounds are also provided. | 12-06-2012 |
20120245166 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH - Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning. | 09-27-2012 |
20120149657 | 2'-FLUORO ARABINO NUCLEOSIDES AND USE THEREOF - A method of treating cancer using certain 2′-fluoro arabino nucleosides is provided. Also provided are compounds represented by the formula: (I & A) wherein R is alkyl; and pharmaceutically acceptable salts thereof; and pharmaceutical compositions containing these compounds. | 06-14-2012 |
20120136142 | Vaccine Compositions For Marburg Virus - Methods and immunogenic compositions for generating an immune response against Marburg virus are provided. The immunogenic composition includes antigens obtained from a Marburg viral strain in combination with an oleanolic acid triterpene adjuvant. | 05-31-2012 |
20110301165 | METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1: | 12-08-2011 |
20110218170 | USE OF 2'-DEOXY-4'-THIOCYTIDINE AND ITS ANALOGUES AS DNA HYPOMETHYLATING ANTICANCER AGENTS - Compounds represented by the formulae: | 09-08-2011 |
20110212073 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS - A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a | 09-01-2011 |
20110191036 | DIRECT CONTACT FORCE MEASUREMENT SYSTEM - A system for measuring forces from a rotating object is presented. In one aspect, the measurement system has a plurality of strain sensors that are configured to attach to the sidewall of a tire of a vehicle and measure the strain on the sidewall. The system can also have a data processor to relate the strain on the sidewall to the normal force exerted on the driving surface from the tire. | 08-04-2011 |
20100216797 | PREPARATION OF THIOARABINOFURANOSYL COMPOUNDS AND USE THEREOF - Patients suffering from cancer are treated by being administered a compound represented by the following formula: | 08-26-2010 |
20100204338 | ANTI-ANGIOGENIC AGENTS AND METHODS OF USE - The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine. | 08-12-2010 |
20100129317 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES - Azole nucleosides represented by the formulae (I) and (II); wherein A=C or N B═C or N X═H; C | 05-27-2010 |
20100120745 | ANTI-ANGIOGENIC AGENTS AND METHODS OF USE - The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadine, Perphenazine, Bithionol, and Clomipramine. | 05-13-2010 |
20100120679 | Targeting NBS1-ATM Interaction To Sensitize Cancer Cells To Radiotherapy And Chemotherapy - Provided herein are compositions and methods for use in sensitizing cancer cells to radiation and chemotherapy. | 05-13-2010 |
20090239892 | PYRIDOMORPHINANS, PYRIDAZINOMORPHINANS AND USE THEREOF - Compounds represented by the formula: | 09-24-2009 |
20080312329 | Nonpeptide Inhibitors of Matrix Metalloproteinases - Disclosed are selective inhibitors of matrix metalloproteinases represented by the following formula (I). | 12-18-2008 |
20080234275 | METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1: | 09-25-2008 |